These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 22371636)

  • 1. Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis.
    Eltawil KM; Laryea M; Peltekian K; Molinari M
    World J Gastroenterol; 2012 Feb; 18(8):767-77. PubMed ID: 22371636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis.
    Jiang Q; Jiang XH; Zheng MH; Jiang LM; Chen YP; Wang L
    Eur J Gastroenterol Hepatol; 2008 Nov; 20(11):1064-70. PubMed ID: 19047837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-Analysis.
    Wu D; Wu SM; Lu J; Zhou YQ; Xu L; Guo CY
    Gastroenterol Res Pract; 2013; 2013():236963. PubMed ID: 23653636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rifaximin for the treatment of hepatic encephalopathy.
    Lawrence KR; Klee JA
    Pharmacotherapy; 2008 Aug; 28(8):1019-32. PubMed ID: 18657018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of rifaximin in management of hepatic encephalopathy.
    Wahib AA; El-Deen Salem MN; Ahmed MA; El-Dessouky YM; El-Tiby DM; El-Mola K; El-Sayed AM
    J Egypt Soc Parasitol; 2014 Dec; 44(3):677-85. PubMed ID: 25643509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review with network meta-analysis: the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy.
    Zhu GQ; Shi KQ; Huang S; Wang LR; Lin YQ; Huang GQ; Chen YP; Braddock M; Zheng MH
    Aliment Pharmacol Ther; 2015 Apr; 41(7):624-35. PubMed ID: 25684317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy.
    Ahire K; Sonawale A
    J Assoc Physicians India; 2017 Aug; 65(8):42-46. PubMed ID: 28799305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?
    Gluud LL; Dam G; Borre M; Les I; Cordoba J; Marchesini G; Aagaard NK; Vilstrup H
    Metab Brain Dis; 2013 Jun; 28(2):221-5. PubMed ID: 23275147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rifaximin for treatment of hepatic encephalopathy.
    Maclayton DO; Eaton-Maxwell A
    Ann Pharmacother; 2009 Jan; 43(1):77-84. PubMed ID: 19092143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is rifaximin better than nonabsorbable disaccharides in hepatic encephalopathy?: A meta-analysis.
    Cheng J; Chen Y; Cao W; Zuo G
    Medicine (Baltimore); 2021 Dec; 100(51):e28232. PubMed ID: 34941089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rifaximin for the treatment of hepatic encephalopathy.
    de Melo RT; Charneski L; Hilas O
    Am J Health Syst Pharm; 2008 May; 65(9):818-22. PubMed ID: 18436728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rifaximin, a nonabsorbed oral antibiotic, in the treatment of hepatic encephalopathy: antimicrobial activity, efficacy, and safety.
    Williams R; Bass N
    Rev Gastroenterol Disord; 2005; 5 Suppl 1():S10-8. PubMed ID: 15976747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacotherapy for hepatic encephalopathy.
    Phongsamran PV; Kim JW; Cupo Abbott J; Rosenblatt A
    Drugs; 2010 Jun; 70(9):1131-48. PubMed ID: 20518580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy.
    Kimer N; Krag A; Møller S; Bendtsen F; Gluud LL
    Aliment Pharmacol Ther; 2014 Jul; 40(2):123-32. PubMed ID: 24849268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
    Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
    Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis.
    Huang E; Esrailian E; Spiegel BM
    Aliment Pharmacol Ther; 2007 Oct; 26(8):1147-61. PubMed ID: 17894657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy for the treatment and prevention of hepatic encephalopathy.
    Mohammad RA; Regal RE; Alaniz C
    Ann Pharmacother; 2012 Nov; 46(11):1559-63. PubMed ID: 23092866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rifaximin: new therapeutic indication and future directions.
    Rivkin A; Gim S
    Clin Ther; 2011 Jul; 33(7):812-27. PubMed ID: 21741091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disaccharides in the treatment of hepatic encephalopathy.
    Sharma P; Sharma BC
    Metab Brain Dis; 2013 Jun; 28(2):313-20. PubMed ID: 23456517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial.
    Mas A; Rodés J; Sunyer L; Rodrigo L; Planas R; Vargas V; Castells L; Rodríguez-Martínez D; Fernández-Rodríguez C; Coll I; Pardo A;
    J Hepatol; 2003 Jan; 38(1):51-8. PubMed ID: 12480560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.